
During a year when healthcare stocks, especially biotechnology, have lagged so deeply behind the overall market, it’s particularly noteworthy that Incyte Corporation (NASDAQ: INCY) has managed to stand out. The stock is up 21.6% year-to-date (YTD), not only outperforming its struggling sector but also surpassing the benchmark S&P 500.
This strength stems from an impressive second-quarter earnings report and management commentary that have fueled recent momentum. With the stock now edging toward a potential multi-year breakout, the question becomes: can Incyte deliver on its ambitious earnings forecasts and pipeline promises?